A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers

Phase 0 Completed 12 enrolled Disruptive Pharma CTC Clinical Trial Consultants AB · collab

RandomizedCrossoverOpen-labelTreatment

Summary

The study aims to assess the pharmacokinetics and safety of DPH001, an amorphous formulation of sorafenib, compared to Nexavar® in healthy volunteers.

Timeline

Start: 2025-02-10
Primary completion: 2025-03-10
Completion: 2025-03-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sorafenib	Small molecule	100 mg	Oral
Subject	Sorafenib	Small molecule	200 mg	Oral

Indications

No indication recorded.